SOMAÍ Pharmaceuticals

Home
SOMAÍ Pharmaceuticals

Somai is fast becoming one of the most recognized and well-developed pharmaceutical brands in the EU.

A leading EU-GMP European vertically integrated Multi-Country Operator (MCO) company with a global footprint of distribution for the largest and most advanced EU GMP-certified cannabinoid-containing pharmaceutical extract portfolio Somai Pharmaceuticals LTD is a European pharmaceutical and biotech company centered on manufacturing in Lisbon, Portugal and distribution of EU GMP-certified cannabinoi

d-containing pharmaceuticals throughout the European Union and globally. Somai emphasizes scientific pharmacology applications with EU-GMP standards to deliver treatments to the endocannabinoid system, effectively and with consistency across all markets. Somai's product development knowledge was honed in the competitive American market, and is the largest and most advanced cannabinoid manufacturing facility across legal European markets producing medicines products and registered API's. Somai has brought together an all-star team of scientists and KOL's from around the world with various clinical experiences to guide Somai's product development and acceptance globally. Somai stresses education and continual R&D, which started from the USA as transformative developments, to help EU doctors and patients properly diagnose and treat the individual indications by providing variable dosage choices. Somai’s primary goal is producing the most advanced products with the most innovative delivery methods to create maximum bioavailability and healing for patients. As a global biotech player concentrating on cannabinoids, Somai has a unique pipeline of current and future products that will be on the market starting in late 2022. They already boast one of the largest IP (Intellectual Property) vaults of APIs that weren’t accessible to Europe until recently. Somai’s near term products conform to the highest standards of herbal medicine (ACM) and specialized cannabinoid API’s for R&D, but also keeps a steady eye on the horizon of future clinical trials for their proprietary pipeline, setting it up to be well positioned for the next decade.

22/07/2025

From Wall Street to Lisbon, from real estate to cannabis pharmaceuticals — Michael Sassano 's journey is anything but ordinary. In this episode of Innovating Cannabis, Michael breaks down his global strategy for SOMAÍ, a cannabinoid pharmaceutical company now operating in 12 countries — with sights set on 18 by year-end.

Tune in as he shares:
🔹 The lessons from building 16 large-scale cultivation facilities in the U.S.
🔹 The advantages of being early in Europe
🔹 What it really takes to be a successful Multi-Country Operator (MCO)
🔹 The roadblocks and opportunities in global cannabis expansion
Hosted by Pam Chmiel, Innovating Cannabis explores the people and companies shaping the future of the industry.

🎧 Listen now: https://www.youtube.com/watch?v=jG2h6F3Z4-w&ab_channel=InnovatingCannabisPodcast

21/07/2025

Wir freuen uns riesig, unsere Teilnahme und unser Engagement bei der HAMCAN Messe in Hamburg bekannt zu geben! SOMAI ist nicht nur dabei, sondern auch stolzer Sponsor mehrerer spannender Events.

Besuchen Sie uns und erfahren Sie mehr über unsere Arbeit und unsere Vision für die Zukunft des medizinischen Cannabis.

Unsere Highlights auf der HAMCAN:
🔥 B2B Barbecue (Sponsor)
Wann: Freitag, 25. Juli, 21:00 - 24:00 Uhr
Wo: Hotel Melia Innside Hamburg Hafen

🗣️ Patienten Roundtable (Veranstalter)
Treten Sie mit uns in den Dialog! Dr. medic Vlad Gavril wird Einblicke in die Wichtigkeit von Terpenen geben und unsere Studie zum Reinigungsprozess bei SOMAI vorstellen.
Wann: Samstag, 26. Juli, 13:00 - 15:00 Uhr
Wo: 1. Stock - Ehemaliges Hauptzollamt Hamburg Hafen, Alter Wandrahm 20, 20457 Hamburg

🎉 Offizielle Afterparty (Sponsor)
Wann: Samstag, 26. Juli, Beginn: 23:55 Uhr
Wo: 25 Club - Reeperbahn 25, 20359 Hamburg

Wir können es kaum erwarten, Sie dort zu treffen, uns auszutauschen und gemeinsam eine bessere Zukunft für medizinisches Cannabis zu gestalten!

15/07/2025

Talent doesn’t recognise borders. Neither do we.

Our international team brings deep expertise and a fresh perspective to cannabinoid innovation — uniting pharma, biotech and life sciences in one ecosystem of excellence.

💡 Global minds. Singular purpose.

14/07/2025

From Sanctuary Cove to Sydney, and everywhere in between - it’s been a big few months at SOMAÍ Australia!

So far this year, we have:
🔷 Launched multiple new ranges to improve patient compliance
🔷 Sponsored UIC, the ANZCCP Conference and Melbourne’s first cannabis trivia night
🔷 Hosted our CEO Michael Sassano in Australia
🔷 Celebrated a Cannabiz Awards nomination with our MSL team
🔷 Partnered with Dan Herer of Jack Herer Brands for a standout event at Pumphouse
🔷 Connected with GPs in Terrigal and all throughout the east coast
🔷 Teased the upcoming launch of Berner’s Signature Series
🔷Expanded our team and showcased our growing portfolio

And… we’re just getting started!

11/07/2025

🌱 Meet Nigel Gale, our new Director of Grow & Production at SOMAÍ!

With a PhD in Plant Physiological Ecology from the University of Toronto and nearly a decade at the intersection of cannabis R&D and large-scale operations, Nigel brings global expertise to our cultivation strategy.

He has pioneered seed stability protocols for pharmaceutical development and now leads cultivation at one of Europe’s most advanced EU-GMP indoor facilities.

💬 “SOMAÍ is truly different. We're executing EU GMP at scale while maintaining craft-level attention to detail. Every day brings new innovations, partnerships, and opportunities to raise the bar for medicinal cannabis.”

From growers in Thailand to prescribers in Australia, Nigel’s vision is global—and so is SOMAÍ’s mission to deliver consistent, science-backed flower and derivatives to patients worldwide.

Welcome aboard, Nigel!

10/07/2025

🚨 New article alert from SOMAÍ’s CEO Michael Sassano — now live in Cannabiz!
📰 “ Australia's white label identity crisis: a story of quality, branding and margins”

Michael dives into one of the most pressing issues facing Australia’s booming medical cannabis industry: the rise of indistinguishable white-label brands and the consequences on quality, trust, and pricing.

🔍 Why it matters:
🔵 Patients deserve transparency and consistency
🔵 True brands are built on science, not stickers
🔵 Mature markets move beyond the white-label craze

📖 Read the full article to understand how Australia’s cannabis landscape is evolving — and what the future holds for patients and producers alike: https://www.cannabiz.com.au/australias-white-label-identity-crisis-a-story-of-quality-branding-and-margins/

09/07/2025

When it comes to patient care, options matters.

SOMAÍ’s portfolio is designed to respond to complexity — covering indications, administration routes and therapeutic needs with precision and range.

🧬 From flower to tailored formulations.
🎯 From prescription to result.

08/07/2025

🔙 Throwback to Benzinga’s Cannabis Capital Conference in Chicago — where our Founder & Interim CEO, Michael Sassano, sat down for an exclusive interview, offering sharp insights into the future of cannabis on a global scale.

🎙 From international expansion to regulatory evolution and emerging investment strategies, Michael shared how SOMAÍ continues to lead the charge in shaping the next era of medical cannabis.

💬 If you missed it, now’s your chance to catch a glimpse into the strategic vision that’s redefining pharmaceutical cannabis.

Watch here: https://www.youtube.com/watch?v=vvSB_vZQss8&ab_channel=BenzingaEvents

📍

07/07/2025

🇨🇭 Switzerland: A new chapter in medical cannabis

In his latest article, SOMAÍ Founder & Interim CEO Michael Sassano explores how SOMAÍ and Dascoli Pharma are helping shape the future of cannabis in Switzerland — combining world-class formulations with a patient-first mindset.

From full-spectrum extracts and innovative form factors to local education and access, this collaboration brings science, trust, and modern cannabis care to Swiss patients.

📖 Read the full piece: https://somaipharma.eu/news/the-new-era-of-cannabis-in-switzerland-open-access-and-education-lead-b-somai-and-dascoli-pharma-partnership/

04/07/2025

Meet Renee LePierres, SOMAÍ Australia’s new Business Development Manager - QLD.

With a background spanning multiple industries and a focus on healthcare, Renee brings a passion for purpose-led wellbeing to the SOMAÍ team. Her experience across women’s health and aged care has seen her work closely with healthcare professionals to support patients through significant life transitions—from menopause to breast cancer recovery.

“My journey into medicinal cannabis has been incredibly inspiring. Exploring the industry firsthand has deepened my belief in the power of alternative medicines—and SOMAÍ’s role in driving real change.”
Now focused on building SOMAÍ’s relationships with healthcare professionals, pharmacists, and business owners, Renee is committed to helping expand access to high-quality cannabinoid medicines across Australia.

Welcome aboard, Renee—we’re thrilled to have your energy, empathy, and experience as part of the SOMAÍ journey.

03/07/2025

Some companies operate locally.
SOMAÍ operates globally.

From regulatory compliance to last-mile delivery, our international footprint ensures every solution arrives with the precision and confidence it was designed for.

🌍 One company. Many markets.

01/07/2025

SOMAÍ, in collaboration with Universidade Lusófona - Centro Universitário Lisboa, has published a groundbreaking peer-reviewed paper in the Pharmaceuticals journal titled “Process Development for GMP-Grade Full Extract Cannabis Oil: Towards Standardized Medicinal Use.”

The study validates SOMAÍ’s patent-pending process for producing Full-Spectrum Extract Cannabis Oil (FECO), offering new scientific evidence that bridges pharmaceutical precision with consistent, patient-friendly formulations.

“This paper underscores SOMAÍ’s scientific leadership in the cannabis pharmaceutical industry,” said Michael Sassano, Founder and Interim CEO of SOMAÍ. “Our study demonstrates that full-spectrum cannabis formulations can be scientifically structured, reproducible, and pharmaceutically precise—dispelling the misconception that full-spectrum must mean uncontrolled or inconsistent.”

“This research is a step forward in establishing scientific rigor within the medical cannabis field,” said Professor Maria do Céu Costa of Lusófona University. “Our findings show that with the right methodology, it is possible to preserve the integrity of the plant while achieving consistency, safety, and improved patient acceptance. It’s a meaningful contribution to both science and therapeutic innovation.”

Read the full text of the publication online at MDPI: https://www.mdpi.com/1999-4923/17/7/848

Address

Website

http://www.somaipharma.eu/

Alerts

Be the first to know and let us send you an email when SOMAÍ Pharmaceuticals posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to SOMAÍ Pharmaceuticals:

Shortcuts

Address
Alerts
Contact The Practice
Want your practice to be the top-listed Clinic?

Country:

City: